Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors

• Published in: Xenobiotica Vol. 44; no. 1; pp. 17 - 27
• Main Authors: Desbans, C., Hilgendorf, C., Lutz, M., Bachellier, P., Zacharias, T., Weber, J. C., Dolgos, H., Richert, L., Ungell, A.-L.
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 01.01.2014; Taylor & Francis
• Subjects: Chromatography, High Pressure Liquid; Cryopreservation - methods; CYP450 inhibition; Cytochrome P-450 CYP3A - metabolism; DDI risk; Drug Interactions - physiology; Hepatocytes - metabolism; hepatocytes suspension; Humans; ketoconazole; Mass Spectrometry; Metabolic Networks and Pathways - physiology; Models, Biological; Pharmaceutical Preparations - metabolism; preclinical
• ISSN: 0049-8254; 1366-5928; 1366-5928
• DOI: 10.3109/00498254.2013.809617

Abstract 1.  It has previously been demonstrated that metabolism of drugs via a single enzymatic pathway, particularly CYP3A4, is associated with increased risk for drug-drug interactions (DDI). Quantitative experimental systems as well as integrated prediction models to assess such risk during the preclinical phase are highly warranted. 2.  The present study was designed to systematically investigate the performance of human cryopreserved hepatocytes in suspension to predict fraction metabolized via CYP3A (fmCYP3A) by assessing the ketoconazole sensitive intrinsic clearance (CLint) for five prototypical CYP3A substrates with varying degree of CYP3A dependent CLint in twelve individual hepatocyte batches. 3.  We demonstrate that in contrast to well predicted mean hepatic metabolic clearance (CLH) and mean fmCYP3A data, the variability in CYP3A contribution for compounds having multiple metabolic pathways cannot be predicted from inhibition experiments using ketoconazole as inhibitor. Instead, data in the present paper indicate that the variability is larger after inhibition of CYP3A for compounds having multiple metabolic pathways. 4.  It is therefore recommended to estimate the average CLint and fmCYP3A for a given test compound in a series (n = 10) of individual human hepatocyte batches.